Mathew Wehbe
Medical Oncology · Des Moines, IANPI 1619186368
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $100,434 of the $119,901 with a category attached, or 83.8%. Jazz Pharmaceuticals Inc. accounts for 75.4% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $44,751, more than ten times the $15 reported in 2019. Among medical oncology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $1042.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$90K
- AstraZeneca$29K
- Myriad Genetic Laboratories, Inc.$269
- Johnson & Johnson$60
- AVEO Pharmaceuticals, Inc.$40
- Regeneron Healthcare Solutions, Inc.$40
- plus $74 from 4 others
Across 1 payment — averaging $1000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$1K
What the payments were for
- Consulting fees$6,5105%
- Speaking & faculty fees$100,43484%
- Travel & lodging$9,7468%
- Food & beverage$3,1593%
- Education$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 79 | $90,364 |
| AstraZeneca | 22 | $29,054 |
| Myriad Genetic Laboratories, Inc. | 4 | $269 |
| Johnson & Johnson | 3 | $60 |
| AVEO Pharmaceuticals, Inc. | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $40 |
| Dendreon Pharmaceuticals LLC | 1 | $32 |
| Astellas Pharma US Inc | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$119,901 in reported general payments places this provider in the 95th percentile of 47 medical oncology providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 11 | $132,439 |
| Abiraterone Acetate | 16 | $62,581 |
| Anastrozole | 101 | $1,771 |
| Letrozole | 37 | $619 |
| Sucralfate | 14 | $609 |
| Tamoxifen Citrate | 14 | $482 |
| Acyclovir | 24 | $311 |
| Hydroxyurea | 17 | $267 |
| Pregabalin | 12 | $263 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $230 |
| Ondansetron OdtOndansetron | 23 | $223 |
| Dexamethasone | 12 | $220 |
| Pantoprazole Sodium | 16 | $113 |
| Prednisone | 21 | $110 |
| Prochlorperazine Maleate | 11 | $91 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Des Moines
- Giselle MeryDes Moines$12K
- Emily BrugioniDes Moines$6K
- Millicent AmankwahDes Moines$3K
- Steven HeddingerDes Moines$3K
- Christian SchultheisDes Moines$432
- Matthew HillDes Moines$378
- Magdy ElsawyDes Moines$353
- Robert BehrensDes Moines$345
- Bradley HiattDes Moines$148
- Sydney BrehanyDes Moines$141
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.